Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands

• Main Authors: Bill, R. (Author), Deschler, D.G (Author), Pai, S.I (Author), Park, J.C (Author), Pittet, M.J (Author), Sadow, P.M (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2022
• Subjects: head and neck cancer; larotrectinib; minor salivary glands; NTRK fusion; secretory carcinoma
• Online Access: View Fulltext in Publisher
• ISBN: 25738348 (ISSN)
• DOI: 10.1002/cnr2.1491

Background: Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease. Case: We present the case of a female patient with secretory carcinoma arising in the base of tongue with persistent disease after debulking surgery and definitive chemoradiation. As an alternative to salvage surgery, which would have resulted in significant impairment of swallowing and speech function, a targeted therapy with the TRK-inhibitor larotrectinib against an identified ETV6-NTRK3 fusion product was initiated. Larotrectinib treatment has been well tolerated, resulted in durable complete response and the patient maintains good swallowing and speech function. Conclusion: The presented case underscores the importance of the accurate diagnosis of secretory carcinoma. It further highlights the impact of molecular testing as targeted therapies may play an important role in the management of advanced salivary gland cancers. © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.